Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Huazhong University of Science and Technology
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06968624CT.gov Ketamine for Postherpetic Neuralgia With Depression | — | Not Yet Recruiting | — | — | — |
NCT06896994CT.gov Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia | — | Recruiting | — | — | — |
NCT01116531CT.gov Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Postherpetic Neuralgia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Duloxetine (this asset) | Huazhong University of Science and Technology | Approved | B · 62 |
| Lidocaine | Seoul National University Hospital | P4 | BBB |
| Pregabalin | Neurodawn Pharmaceutical Co., Ltd. | P4 | BBB |
| Gabapentin | University of Medicine and Pharmacy at Ho Chi Minh City | P4 | BBB |
| Capsaicin | Astellas Pharma Europe Ltd. | P4 | BBB |
| Crisugabalin | Haisco Pharmaceutical Group Co., Ltd. | P3 | BB |
| (±)-Tramadol | Astellas Pharma Inc | P4 | BB |
| Marcaine | Shirong Tan | P4 | BB |
| Eslicarbazepine Acetate | Bial - Portela C S.A. | P3 | BB |
+42 more in the Postherpetic Neuralgia cohort
Other indications for Duloxetine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Diabetic Neuropathy | — | P4 | A · 81 |
| Fibromyalgia | — | P4 | BBB · 74 |
| Osteoarthritis | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Duloxetine in Postherpetic Neuralgia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/duloxetine-postherpetic-neuralgia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →